Imaging Biomarkers of Tissue Microstructure and Vasculature as Predictors of Glioblastoma Multiforme Response to Treatment With Bevacizumab for Progressive Disease
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 13
- 试验地点
- 1
- 主要终点
- MRI to show differences between bevacizumab responses
研究概览
简要总结
This study is for subjects with a diagnosis of a brain tumor called glioblastoma that is being treated with bevacizumab. This study will use a new MRI technique to compare the images of blood vessels and tumor structure to the effectiveness of bevacizumab.
详细描述
This study is for subjects with a diagnosis of a brain tumor called glioblastoma that is being treated with bevacizumab. Bevacizumab is a drug that your doctor believes is the best treatment option available to subjects at this time for this type of tumor. Bevacizumab affects the growth of blood vessels by tumors such as glioblastoma, thus effectively starving the tumor of oxygen and food.
Magnetic Resonance Imaging (MRI) is a test done by a machine in the radiology department that takes pictures of your body using special magnets, rather than X-rays. With a new MRI scan technique the investigators can take very, very detailed images of the vessel and tumor structure. This project will allow us to compare the images of vessel and tumor structure to the effectiveness of Bevacizumab as a treatment option. With this project the investigators will hopefully develop an accurate way to predict whether or not Bevacizumab will be an effective treatment option for patients.
研究设计
- 研究类型
- Observational
- 观察模型
- Case Only
- 时间视角
- Prospective
入排标准
- 年龄范围
- 18 Years 至 80 Years(Adult, Older Adult)
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age between 18 and 80 years of age
- •Progressive glioblastoma patients who have been planned to receive bevacizumab
- •Karnofsky Performance Status 50 or above (vd. Appendix A)
- •Established pathologic diagnosis of glioblastoma
- •Prior treatment with radiation and chemotherapy
- •Neuroimaging progression of glioblastoma
- •Able and willing to provide informed consent (or consent of a guardian)
排除标准
- •Contraindication to MRI
- •Contraindication to bevacizumab therapy
- •Concurrent enrollment in other neuroimaging trials
- •Prior therapy with bevacizumab
- •Known hypersensitivity to MRI contrast
- •Females who are nursing or pregnant
结局指标
主要结局
MRI to show differences between bevacizumab responses
时间窗: 1 month
The MRI parameters will help show the differences between bevacizumab-responsive and bevacizumab non-responsive recurrent glioblastoma
次要结局
- Progression Free Survival at 3 months(3 months)
